{"id":132675,"date":"2022-08-09T08:18:23","date_gmt":"2022-08-09T12:18:23","guid":{"rendered":"https:\/\/44.250.171.167\/?p=132675"},"modified":"2022-10-06T04:50:14","modified_gmt":"2022-10-06T08:50:14","slug":"glenmark-life-sciences-limited-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Glenmark Life Sciences Limited Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><span class=\"embed-youtube\" style=\"text-align:center; display: block;\"><iframe loading=\"lazy\" class=\"youtube-player\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/02Igs_HUAfo?version=3&#038;rel=1&#038;showsearch=0&#038;showinfo=1&#038;iv_load_policy=1&#038;fs=1&#038;hl=en-US&#038;autohide=2&#038;wmode=transparent\" allowfullscreen=\"true\" style=\"border:0;\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-presentation allow-popups-to-escape-sandbox\"><\/iframe><\/span><\/p>\n<p><strong>Key highlights from Glenmark Life Sciences Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/GLS\/\">GLS<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:14:56] Neha Manpuria from Bank of America asked about the generic API business, ex-COVID growth, how much of the growth is volume vs. pricing that has flown through. Yasir Rawjee MD replied that the growth is mainly volume growth. However, GLS was able to pass quite a bit of price increase to some of its customers on some APIs.<\/li>\n<\/ul>\n<ul>\n<li>[00:19:08] Neha Manpuria from Bank of America asked about RM cost pressure, improvement in pricing and impact on GM. Yasir Rawjee MD replied that the margins on the material side have gone up vs. last quarter, which is mainly driven by softening solvent prices.<\/li>\n<\/ul>\n<ul>\n<li>[00:27:04] Shyam Srinivasan with Goldman Sachs enquired about guidance for FY23 on topline growth and margins. \u00a0Yasir Rawjee MD answered that given the fact that the company has still got three quarters going, it should still come through with around 12% growth for FY23. And on margins, GLS feels the worst is already baked in.<\/li>\n<\/ul>\n<ul>\n<li>[00:29:10] Krish Mehta from Enam Holdings asked about the absolute amount of working capital for 1Q23. Tushar Mistry CFO replied that the working capital is at 168 days. On an absolute number basis, it\u2019s about INR960 crores and a major part of that is from inventory which is at about INR600 crores.<\/li>\n<\/ul>\n<ul>\n<li>[00:29:59] Krish Mehta from Enam Holdings enquired about the guidance of working capital for the rest of year. Tushar Mistry CFO answered that the company expects to see this levels remain at this level for the near term.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:46] Tarang Agrawal with Old Bridge Capital asked new launches, in which markets were the launches and the segments. Yasir Rawjee MD said that the launches were in the US and in the CNS and cardiovascular segment.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:54] Tarang Agrawal with Old Bridge Capital also asked about the nitrosamine issue still impacting the sartans business in North America. Yasir Rawjee MD replied that it\u2019s the customer taking a call if they want to continue with sartans given the regulatory challenges they face.<\/li>\n<\/ul>\n<ul>\n<li>[00:33:34] Vikas Sharda of NTAsset asked about the PLI benefit, how does it work and the expansion it\u2019s linked to. Yasir Rawjee MD answered that there is a base in FY20 and GLS had to submit the number of APIs where there would be growth. A list of 85 APIs were submitted where GLS could see growth in 5 years. GLS feels it\u2019s in a good positing with these 85 APIs.<\/li>\n<\/ul>\n<ul>\n<li>[00:40:17] Naman Bhansali from Perpetuity Ventures enquired about the dependency on parent company Glenmark Pharma. Yasir Rawjee MD answered that on the revenue side, 35% came from Glenmark Pharma in 1Q23.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Glenmark Life Sciences Limited (GLS) Q1 FY23 Earnings Concall Q&amp;A Highlights: [00:14:56] Neha Manpuria from Bank of America asked about the generic API business, ex-COVID growth, how much of the growth is volume vs. pricing that has flown through. Yasir Rawjee MD replied that the growth is mainly volume growth. However, GLS [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Glenmark Life Sciences Limited Q1 FY23 Earnings Conference Call Insights #GLS #Q1 #FY23 #earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[8157,1115],"class_list":["post-132675","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-healthcare","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":128559,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-q4-fy22-earnings-conference-call-summary\/","url_meta":{"origin":132675,"position":0},"title":"Glenmark Life Sciences Limited Q4 FY22 Earnings Conference Call Summary","author":"Praveen","date":"April 21, 2022","format":false,"excerpt":"https:\/\/youtu.be\/au71QUL41tY Key highlights from Glenmark Life Sciences Limited (GLS) Q4 FY22 Earnings Concall Q&A Highlights: Neha Manpuria of Bank of America asked if GLS is seeing any issues relative to sourcing of raw materials due to lockdown in China. Yasir Rawjee MD said that the crisis is unlikely to impact\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135226,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":132675,"position":1},"title":"Glenmark Life Sciences Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"October 27, 2022","format":false,"excerpt":"https:\/\/youtu.be\/FHgUfHa30gw Key highlights from Glenmark Life Sciences Limited (GLS) Q2 FY23 Earnings Concall Management Update: [00:02:53] GLS said that the demand softness did not impact its business significantly due to the mid-volume and high-value products it offers. Q&A Highlights: [00:14:51] Neha Manpuria from Bank of America asked about the generic\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139447,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":132675,"position":2},"title":"Glenmark Life Sciences Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"January 30, 2023","format":false,"excerpt":"Key highlights from Glenmark Life Sciences Limited (GLS) Q3 FY23 Earnings Concall Q&A Highlights: [00:13:44] Tarang Agrawal of Old Bridge enquired about the fixed cost accretion expectation on the P&L from 1Q24, given the Ankaleshwar and Dahej ramping up. Tushar Mistry CFO replied that on a QonQ basis, there should\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":144576,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-gls-q4-fy23-earnings-concall-transcript\/","url_meta":{"origin":132675,"position":3},"title":"Glenmark Life Sciences Limited (GLS) Q4 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"April 28, 2023","format":false,"excerpt":"Glenmark Life Sciences Limited (NSE:GLS) Q4 FY23 Earnings Concall dated Apr. 28, 2023. Corporate Participants: Soumi Rao\u00a0--\u00a0General Manager, Corporate Communications Yasir Rawjee\u00a0--\u00a0Managing Director and Chief Executive Officer Tushar Mistry\u00a0--\u00a0Chief Financial Officer Unidentified Speaker\u00a0-- Analysts: Tarang Agarwal\u00a0--\u00a0Old Bridge Capital -- Analyst Neha Manpuria\u00a0--\u00a0Bank of America -- Analyst Madhusudan Kela\u00a0--\u00a0MK Ventures --\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":136448,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-gls-q2-fy23-earnings-concall-transcript\/","url_meta":{"origin":132675,"position":4},"title":"Glenmark Life Sciences Limited (GLS) Q2 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"October 21, 2022","format":false,"excerpt":"Glenmark Life Sciences Limited (NSE:GLS) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Soumi Rao -- Head - Corporate Communications Yasir Rawjee -- Managing Director and Chief Executive Officer Tushar Mistry -- Chief Financial Officer & Senior Vice President Analysts: Neha Manpuria -- Bank of America -- Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131835,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":132675,"position":5},"title":"Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 1, 2022","format":false,"excerpt":"Key highlights from Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Management Update: SUNPHARMA recorded the highest ever quarterly revenue in 1Q23, with sales increasing 14% YonY, excluding the contribution of 1Q22. SUNPHARMA\u2019s current generic pipeline for the US includes 89 ANDAs and 13 NDAs awaiting approval with the\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/132675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=132675"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/132675\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=132675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=132675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=132675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}